Clinical trials are research studies involving human beings that are investigating specific questions. Typically, patients with a particular illness or disease are enrolled in a study evaluating a new medication or surgical technique that has some advantage over current options, or offers treatment for a condition that has no current treatment options. Most clinical trials are sponsored by large pharmaceutical companies, and consist of three phases. Phase I studies are small, first-in-human trials evaluating the safety of a new medication. Phase II studies passed the initial safety test, and are looking at safety and efficacy in a larger group of patients. Phase III studies are the final step before submitting an application to the FDA for drug approval. They look at the intervention in a large group of patients and focus on efficacy.
A Commitment to Fighting Blindness
In collaboration with the Paul Tornambe Retina Research Foundation and the Scripps Research Institute, Retina Consultants San Diego is dedicated to fighting blindness through cutting-edge bench and clinical research. Over the past 40 years, RCSD has participated in hundreds of studies. These studies are producing revolutionary treatment options, and provide our patients access to next generation medications.
For those who qualify, clinical trial can be very beneficial. In addition to potentially receiving a medication that is more effective, there are no out-of-pocket costs for patients. Insurance is not involved so we can see any eligible patient. Transportation is typically covered, making it easier on the patient and family members. In fact, patients often (but not always) receive a $75 to $100 stipend per visit. More importantly, patients have an opportunity to contribute to science and future treatment options in a meaningful way.
Currently-enrolling or upcoming clinical trials are looking at new treatment options for the following conditions:
- Diabetic macular edema and diabetic retinopathy
- Wet age-related macular degeneration
- Dry macular degeneration and associated geographic atrophy
- Retinal vein occlusion with macular edema
Feel free to email our Clinical Research Coordinator, Judy Nisbet, regarding any questions or potential candidates. Judy can be reached at [email protected] or at 858-451-1911.